New HPV vaccine tested against established option in african youth
NCT ID NCT07256912
Summary
This study aims to compare how well two different HPV vaccines work when given as a single dose to prevent cervical cancer. Researchers will give either the CERVAVAC or Gardasil vaccine to about 1,266 Zambian girls, women, and boys aged 9-20 and track their immune responses over two years. The goal is to see if the newer CERVAVAC vaccine works as well as the established Gardasil vaccine.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER PREVENTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chipata and Matero First Level Hospitals
Lusaka, Zambia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.